Proactiveinvestors recommends
Additional Information
Market: AMEX
Sector: Pharmaceuticals & Biotechnology
EPIC: RNN
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Rexahn Pharmaceuticals
www.rexahn.com

Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Full Rexahn Pharmaceuticals profile here
Is RNN a Buy, Sell or Hold?Get your FREE analysis of RNN
Pdf

Rexahn Pharmaceuticals publishes anti-cancer compounds study in medical journal

9th Nov 2010, 9:24 am

Rexahn Pharmaceuticals (NYSE Amex: RNN) said Monday it published a study demonstrating the potent anticancer activity of its quinoxalinyl-piperazine drug compounds in a medical journal.

The study, published in the Bioorganic & Medicinal Chemistry, showed that the compounds "strongly inhibit" the growth of human cancer cells through programmed cell death, including colorectal cancer cells that were resistant to other cancer treatments.

The company said that quinoxalinyl-piperazine also has a synergistic toxic effect on cells when combined with several known cancer drugs such as paclitaxel, doxorubicin, cisplatin, gemcitabine or 5-fluorouracil.

During the trial, it was proven that with drug resistant HCT-15 cancer cells, the company's compounds had a stronger anti-cancer effect than paclitaxel, decreasing cancer growth by 70-fold, the company said.

"This result implies that the compound may control and overcome drug resistance," Rexahn concluded in a statement.

Rexahn currently has three drug candidates in phase II clinical trials, including Archexin, Serdaxin, and Zoraxel, and a pipeline of preclinical compounds to treat multiple cancers and CNS disorders.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.